aibio.space: Biotech IR News, Financings and Offerings

Top news

  1. Financings ·

    PTC Therapeutics authorizes $500 million buyback with no timetable or minimum

  2. Debt Financing ·

    Rockwell Medical borrows $125 million from Vantive to buy its dialysis business

  3. Financings ·

    MediWound sells $15 million of shares below market in H.C. Wainwright bought deal

  4. Financings ·

    Cardiol opens a US$75 million Jefferies share sale with its stock near US$1

  5. Debt Financing ·

    Tevogen pays off Patel loan in stock and gives CEO 50 million shares

  6. Debt Financing ·

    SciSparc sells $3,000,000 discounted convertible note to repeat financier L.I.A. Pure Capital

  7. Financings ·

    AEON cuts warrant price 38% to $0.20, below its July offering price, to collect about $6.2 million

  8. Listings ·

    InMed shareholders back Mentari merger with cash lasting only into mid-November

  9. Company Updates ·

    KALA shareholders give the board room for another reverse split

  10. Distress ·

    Supernus and Indivior close merger and borrow $650 million to pay Indivior holders

  1. Financings ·

    Theriva sells ribaxamase for $350,000 upfront and hands $140,000 to PREV

    Biossil Labs takes over SYN-004 and its costs, but Theriva's larger payments depend on approvals and sales, and a share goes to PREV ABR LLC.

    TOVX
  2. Debt Financing ·

    AquaBounty borrows $500,000 from the parent of Univest, its placement agent and a 10.7% holder

    The unsecured bridge note pays 9% and has no covenants or equity feature. Univest Securities has collected placement fees on four raises since October 2025 and holds first-refusal rights on future deals and a sale.

    AQB
  3. Debt Financing ·

    ABVC sells $4.1 million of discounted convertible notes for $3.39 million and pays Lind $625,000 to end lawsuit

    The notes mature June 30, 2027 and convert at 85% of recent prices down to a $0.20 floor. ABVC had $31,944 in cash at June 30 and reports substantial doubt about its ability to continue as a going concern.

    ABVC
  4. Distress ·

    Karyopharm files Chapter 11 with Ayrmid merger plan that cancels its common stock

    Lenders and noteholders would own 55% of the combined company and receive myelofibrosis sales rights. Shareholders get nothing, and Karyopharm expects its stock to be delisted.

    KPTI
  5. Distress ·

    Regen Biopharma, with $239 in cash at June 30, signs $125,000 note and $10 million equity line with Coventry

    Most of what the note paid out went to retire $71,557 of older convertible debt. The equity line sells stock at 80% of the lowest recent price and cannot start until an S-1 is effective.

    RGBP
  6. Debt Financing ·

    Repligen announces $1.0 billion private convertible notes transaction

    The 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37.

    RGEN
  7. Debt Financing ·

    Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J

    Horizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.

    PTHS
  8. Financings ·

    ProKidney files $650 million shelf with $200 million Jefferies sales program

    ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.

    PROK
  9. Financings ·

    Lexeo Therapeutics files $300 million shelf registration

    Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.

    LXEO
  10. Financings ·

    INmune Bio raises $4.50 million in registered direct offering with warrants

    The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.

    INMB
  11. Debt Financing ·

    FOXO to buy Ludwig Enterprises preferred stock with majority voting power

    FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.

    FOXO
  12. Debt Financing ·

    Altimmune draws $10.0 million third tranche from Hercules loan facility

    Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.

    ALT

Company highlights

Latest from the companies we cover in depth, with our Investor Rank (opinion only, not a recommendation).

News by section

Financings

Debt Financing

Distress

Listings

Mergers

2,820 companies. A desk for each one.

Every listed biotech and pharma company gets its own front page at its own address, with its news and our view of it.

Companies with a full desk are marked. Every other company shows its listing and our coverage.

    Catalyst calendarDates the desks are watching, and recent decisions

    1. Nov 14, 2026Pending
    2. Nov 14, 2026Pending
    3. Nov 14, 2026Pending
    4. Nov 25, 2026Pending
    5. Nov 27, 2026Pending
    6. Nov 27, 2026

      GSK: FDA decision on neladalkib in ALK-positive NSCLC

      Target date as reported by the company

      Pending

    Where the desks are

    2,820

    Public drug developers and pharmaceutical makers in our directory, across 58 countries and territories. The US has the most. China, India and South Korea together have more.

    Source: aibio.space company directory, research date October 22, 2026. One row per issuer.

    Companies by country

    • United States680
    • China417
    • India219
    • South Korea206
    • Taiwan140
    • Japan93
    • Canada92
    • Sweden74

    Free membership

    Read the companies you follow. Subscribe free for email updates.

    Each desk collects the company's filings, press releases and outside coverage, and adds our view of the science, the odds and the balance sheet.

    Free membership

    Read freely. Subscribe for email updates.

    Read every story, desk and company profile for free. Subscribe if you would like updates and offers by email. Unsubscribe in one click.

    How membership works

    Settings

    Text size
    Motion

    Stops the moving share lists on the front page.

    Your choices are saved in this browser only.

    Free membership

    Get aibio.space by email, free

    Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

    No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.